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1. Introduction
Photodynamic therapy (PDT) has attracted 
great attention in recent years due to the 
noninvasive nature, high specificity, con-
trollability, and insignificant side effects 
compared with traditional surgery, chemo-
therapy, and radiotherapy.[1] The key ele-
ment for PDT is that highly cytotoxic 
reactive oxygen species (ROS) generated by 
the photosensitizers (PSs) upon irradiation 
lead to cell apoptosis and necrosis.[2] An 
excellent PS is crucial for the therapeutic 
efficacy of PDT. At present, most PSs for 
PDT are based on organic dyes, including 
boron dipyrromethene (BODIPY), por-
phyrin, and their derivatives.[3] However, 
the reported PSs possess several draw-
backs: (i) the relatively low molar extinc-
tion coefficient results in high dosages and 
longer irradiation time;[4] (ii) the poor water 
solubility and stability severely hinder 
their application in biological conditions;[5] 
(iii) undesirable aggregation-caused 
The singlet oxygen (1O2) generation ability of a photosensitizer (PS) is 
pivotal for photodynamic therapy (PDT). Transition metal complexes are 
effective PSs, owing to their high 1O2 generation ability. However, non-neg-
ligible cellular toxicity, poor biocompatibility, and easy aggregation in water 
limit their biomedical applications. In this work, a series of red-emitting 
aggregation-induced emission (AIE) Ir(III) complexes containing different 
numbers of Ir centers (mono-, di-, and trinuclear) and the corresponding 
nanoparticles (NPs) AIE-NPs, are designed and synthesized. The increase 
of 1O2 generation ability is in line with the increasing number of Ir centers. 
Compared with the pure Ir(III) complexes, the corresponding NPs offer 
multiple advantages: (i) brighter emission; (ii) higher phosphorescence 
quantum yields; (iii) longer excited lifetime; (iv) higher 1O2 generation  
ability; (v) better biocompatibility; and (vi) superior cellular uptake. Both in 
vitro and in vivo experiments corroborate that AIE-NPs with three iridium 
centers possess potent cytotoxicity toward cancer cells and effective 
inhibition of tumor growth. To the best of knowledge, this work is the first 
example of NPs of multinuclear AIE Ir(III) complexes as PSs for enhanced 
PDT. This study offers a new method to improve the efficiency of PSs for 
clinical cancer treatments.
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quenching (ACQ) of emission in aqueous media reduces ROS 
generation.[6] Therefore, it is highly desirable to design PSs that 
can circumvent these shortcomings.
An effective method for improving the efficiency of singlet 
oxygen generation is to accelerate the intersystem crossing 
(ISC) by introducing heavy atoms into PSs, such as halo-
gens, transition metals, etc.[7] Especially, Ir(III) complexes 
have attracted considerable attention as PSs because of their 
ideal photophysical properties, large Stokes shift, and high 
ISC ability.[8] For example, Huang and co-workers designed a 
mitochondria-targeted Ir(III) complex as a PS to improve PDT 
effects under hypoxia.[9] An ingenious organoiridium PS that 
can induce specific oxidative attack on proteins within cancer 
cells was constructed by Sadler and co-workers.[10] The pre-
vious reports mainly focused on mononuclear Ir(III) complexes, 
whereas research into multinuclear Ir(III) complexes as PSs has 
been overlooked. We envisaged that additional metal centers will 
increase metal-to-ligand charge transfer (3MLCT), which will 
further result in an increase of molar absorption coefficient, and 
improved generation of 1O2.[11] Multinuclear Ir(III) complexes 
could, therefore, be highly efficient PSs for PDT.
Ir(III) complexes possess non-negligible cellular toxicity and 
water insolubility, resulting in poor biocompatibility and lim-
ited biomedical applications.[12] Recently, the strategy of pol-
ymer-encapsulated nanoparticles (NPs) has successfully solved 
these problems.[13] Unfortunately, the NP formulations are 
not suitable for traditional PSs owing to ACQ of emission.[7a] 
In 2001, Tang and co-workers discovered aggregation-induced 
emission (AIE),[18] by which fluorescence is intensified in an 
aggregate state through restriction of intramolecular motions 
(RIM) which prohibits the dissipation of energy.[15] Since 
then, AIE materials have been exploited in optoelectronic 
and biological applications. Our group has reported dinuclear 
AIE Ir(III) complexes using Schiff bases as both chelate and 
bridging motifs.[16] The flexibility of the diimine spacer permits 
the ligands to rotate and bend freely, and they can adopt the 
optimum coordination geometries of the metal ions. Further-
more, triphenylamine (TPA), with a propeller-like structure and 
strong electron donating ability, has been used to construct red-
emitting AIE molecules.[17] Red emission is desirable as it can 
reduce interference from the background autofluorescence and 
increase the depth of penetration in tissue.[18] Is it possible to 
combine the advantages of multinuclear transition metal com-
plexes and NPs simultaneously to enhance the PDT effect? 
Inspired by this idea, we synthesized a series of red-emit-
ting AIE Ir(III) complexes and their corresponding NPs and 
explored their potential as PSs for clinical cancer treatments.
2. Results and Discussion
In this work, TPA is used as a bridge to obtain Schiff ligands 
which can electronically couple one to three metal centers. A 
series of red-emitting AIE Ir(III) complexes were obtained: 
mononuclear, dinuclear, and trinuclear complexes (Figure 1A), 
named PS1, PS2, and PS3, respectively, with PS1 serving as a 
model for the multinuclear analogs. The corresponding NPs, 
named PS1 NPs, PS2 NPs, and PS3 NPs, were obtained by 
polymer-encapsulation methods (Figure 1B).[19] A schematic 
illustration of how PS3 NPs were successfully used for PDT is 
shown in Figure 1C. The results establish that the NPs possess 
highly effective 1O2 generation ability, good biocompatibility, 
negligible dark toxicity, superior cell uptake, enhanced PDT 
activity, and tumor inhibition.
The synthetic routes to PS1, PS2, and PS3 are shown 
in Scheme S1 (Supporting Information). Their chemical 
structures and purity were validated by proton and carbon 
nuclear magnetic resonance (1H and 13C NMR) spectroscopy 
(Figures S1–S12 and Figures S13–S15, Supporting Informa-
tion), mass spectrometry (Figures S16–S21, Supporting Infor-
mation), and elemental analysis. The X-ray molecular structure 
of PS1 is shown in Figure S23 (Supporting Information). The 
highest occupied molecular orbital (HOMO) and lowest unoc-
cupied molecular orbital (LUMO) distributions of PS1, PS2, 
and PS3 are shown in Figure S22 (Supporting Information). 
Subsequently, the NPs were obtained by using the iridium 
complexes as the core, biocompatible 1,2-distearoyl-sn-glycero-
3-phosphoethanolamine-N-[maleimide(poly(ethylenegl
ycol))-2000] (DSPE-PEG-MAL) as the encapsulation matrix, 
and the HIV-1 transactivator (RKKRRQRRRC) as the surface 
functionalization group (Figure 1B). HIV-1 Tat is the cell pen-
etrating peptide, which can effectively transport NPs into cells.
The UV–vis absorption and photoluminescence (PL) spectra 
of PS1, PS2, and PS3 and the corresponding NPs are shown 
in Figure 2A–C, respectively. The intense absorption bands 
at around 250–350 nm are attributed to spin-allowed (π–π*) 
transitions of the ligands. The weak absorption bands from 
370 to 520 nm are assigned to metal-to-ligand charge transfer 
(3MLCT) and ligand-to-ligand charge transfer (1LLCT) fea-
tures.[20] The molar absorption coefficient at 450 nm increases 
with the number of metal centers for the Ir(III) complexes 
and their NPs in the order: PS1 (ɛ = 7660 m−1 cm−1) <  PS2 
(ɛ = 16 176 m−1 cm−1) < PS1 NPs (ɛ = 17 570 m−1 cm−1) < PS3 
(ɛ = 31 143 m−1 cm−1) < PS2 NPs (ɛ = 43 651 m−1 cm−1) < PS3 NPs 
(ɛ = 72 935 m−1 cm−1) (Figure S25, Supporting Information). The 
absorbance of PS1 NPs and PS3 are 2.29 and 4.07 times higher 
than PS1, respectively. PS1, PS2, and PS3 are almost nonemissive 
in pure tetrahydrofuran (THF) solution (Figure S26, Supporting 
Information). However, PL intensities of PS1, PS2, and PS3 were 
significantly enhanced when the water fraction of water-THF 
mixtures reached 60%, 80%, and 60%, respectively, revealing an 
obvious AIE effect. Compared with the Ir(III) complexes, the cor-
responding NPs exhibit similar emission peaks but with brighter 
emission in water. The PL maxima of PS1, PS2, and PS3 are 652, 
671, and 690 nm, respectively, demonstrating a sequential redshift 
with the increasing number of metal centers. The large Stokes 
shifts and red emission of these PSs can improve the signal/back-
ground ratios by reducing interference from the background.[17a] 
The photoluminescence quantum yields (PLQYs) of PS1, PS2, 
and PS3 NPs (33%, 15%, and 35%, respectively) in water are 
higher than those of the corresponding Ir(III) complexes (11%, 
5%, and 8%, respectively) in THF-water mixtures (Table S1, Sup-
porting Information). The excited-state lifetimes (τ) of PS1 NPs, 
PS2 NPs, and PS3 NPs are 4.92, 5.38, and 4.61 µs in water, while 
those of PS1, PS2, and PS3 are 959.17, 90.32, and 75.98 ns in 
THF-water mixtures, respectively (Table S1 and Figure S27A,B, 
Supporting Information). These results confirmed the successful 
encapsulation of the Ir(III) complexes into the polymer matrix.
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High 1O2 generation ability is imperative for effective PDT.[21] 
The 1O2 generation ability of PS1, PS2, and PS3 and the 
corresponding NPs were evaluated by measuring the absorb-
ance of indocyanine green (ICG) upon light irradiation.[3f,4] 
A continuous decrease of absorbance at 790 nm (the spe-
cific absorption of ICG) was observed upon irradiation of 
ICG (6.5 nmol) solutions containing PS1, PS2, and PS3 and 
the corresponding NPs (10 nmol), respectively (Figure 2D; 
Figure S31, Supporting Information). This decrease in absorb-
ance of ICG is limited due to the low power of the irradiation 
(20 mW cm−2) and the illumination wavelength (450 nm) 
which is outside the absorption range of ICG.[3f,7a] On the contrary, 
negligible attenuation in absorbance was found in three control 
groups: (i) ICG with irradiation; (ii) PS1, PS2, and PS3 and the 
NPs, with irradiation, respectively; (iii) ICG solutions containing 
PS1, PS2, and PS3 and the NPs without irradiation, respectively 
(Figures S28–S30, Supporting Information). These results sug-
gest that the PSs generate 1O2 upon irradiation and show excel-
lent photostability. As shown in Figure 2E, 1O2 generation of 
PS1, PS2, and PS3 and the corresponding NPs conform to first-
order kinetics. The slope follows the order: PS1 (0.00051) < PS2 
(0.00153) <  PS3 (0.00251) <  PS1 NPs (0.00264) <  PS2 NPs 
(0.00419) < PS3 NPs (0.00502). A steeper slope indicates a greater 
ability to generate 1O2. It is worth mentioning that the slopes of 
PS1 NPs and PS3 NPs are 5.17 and 4.92 times higher than for 
PS1 and PS3, respectively. As anticipated, the increase of slope 
is in keeping with the number of metal centers in the PSs, and 
the slopes for the NPs are much higher than for the Ir(III) com-
plexes. The data suggest that within this series PS3 NPs should 
be the most effective for PDT. These results are clearly dis-
tinct from a recent report of monomeric, dimeric, and trimeric 
BODIPY derivatives and their derived NPs.[3g] In the BODIPY 
series increased π-conjugated coupling between the BODIPY 
units induced a redshift in absorption, and produced dually coop-
erative phototherapy. The BODIPY NPs showed no significant 
influence on 1O2 generation compared to the isolated BODIPY 
dyes. This is in contrast to the Ir complexes and their NPs in the 
present study, where 3MLCT transitions play an important role at 
the metal centers and 1O2 generation is improved.
The morphology, size, and stability of the NPs were 
compared.[5c,18] Transmission electron microscopy (TEM) 
images show that the PS1 NPs, PS2 NPs, and PS3 NPs exhibit 
spherical morphology and uniform dispersion in water with 
average diameters of 44, 47, and 45 nm, respectively (Figure 2F, 
inset). Meanwhile, dynamic light scattering (DLS) demon-
strated that the average sizes of PS1 NPs, PS2 NPs, and PS3 
NPs are 73, 83, and 79 nm, respectively (Table S2 and Figure 
S32, Supporting Information). The sizes obtained by DLS are 
Adv. Sci. 2019, 1802050
Figure 1. A) Chemical structures of PS1, PS2, and PS3; B) The synthesis of NPs; C) Schematic illustration of PS3 NPs as PSs for PDT.
www.advancedsciencenews.com
1802050 (4 of 7) © 2019 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.advancedscience.com
larger than those obtained by TEM because a hydrated layer 
forms on the NPs in the aqueous system.[5c] Spherical NPs 
with dimensions of less than 100 nm are more easily endocy-
tosed by cells. In addition, the size and size distributions of PS1 
NPs, PS2 NPs, and PS3 NPs collected in water for 14 d by DLS 
(Figure 2F) were almost unchanged. Such high stability is ben-
eficial to circulation of particles in blood.[5a] Consequently, the 
PS1 NPs, PS2 NPs, and PS3 NPs possess spherical morphology, 
appropriate size, and high stability. These properties will facili-
tate their ensuing application in living cells and animals.
In order to quantitatively evaluate the PDT effect, the 
cytotoxicity of PS1, PS2, and PS3 and the corresponding NPs 
against HeLa cells were measured by 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays. After 
incubation of the HeLa cells with PS1 NPs, PS2 NPs, and PS3 
NPs (0–20 µg mL−1) for 24 h, the cell viability was still higher 
than 95% (Figure 3A), indicating the good cytocompatibility 
and negligible dark cytotoxicity. However, under light irradia-
tion (20 mW cm−2) for 30 min, the cell viability was obvi-
ously reduced (Figure 3B), implying potent phototoxicity. The 
half-maximal inhibitory concentration (IC50) follows the order: 
PS1 NPs (1.1 × 10−5 m) > PS2 NPs (6.3 × 10−6 m) > PS3 NPs 
(1.1 × 10−6 m). A smaller IC50 indicates an improved effect for 
PDT. The PDT effects of Ir(III) complexes PS1, PS2, and PS3 
were evaluated. As shown in Figure 3C,D, they showed some 
dark cytotoxicity but only slight phototoxicity. These results 
clearly demonstrate that polymer-encapsulation is an efficient 
way to address biocompatibility issues, and the PDT effect can 
be improved by increasing the number of metal centers in PSs.
The advantages of effective 1O2 generation ability and low 
half-maximal inhibitory concentration motivated us to further 
investigate intracellular behavior of PS3 NPs. The cellular 
uptake of PS3 and PS3 NPs was investigated in HeLa by using 
confocal laser scanning microscopy (CLSM). The cell nuclei 
were stained with 4,6-diamidino-2-phenylindole (DAPI). As 
shown in Figure 3E, red fluorescence was observed from 
cells treated with PS3 NPs, which is significantly stronger 
than that with PS3. The enhanced cellular uptake is highly 
advantageous to improve PDT. The intracellular 1O2 genera-
tion was also investigated by using 2′,7′-dichlorofluorescein 
diacetate (DCFH-DA) as an indicator (Figure 3F). Before light 
irradiation, negligible green fluorescence was observed from all 
the cells, indicating an absence of 1O2 generation. Conversely, 
green emission was observed from both PS3 and PS3 NPs in 
the presence of irradiation. As expected, the green emission 
from PS3 NPs is obviously stronger than that from PS3, which 
suggests that the 1O2 generation ability of NPs is higher than 
that of the pure Ir(III) complexes. In addition, the PDT effects 
of PS3 and PS3 NPs were also confirmed by the live/dead 
staining experiments (Figure S34, Supporting Information). 
After irradiation, almost all of the cells were killed by PS3 NPs, 
and the efficiency of inducing cell death was higher than that of 
PS3. This result is in accord with the results of the MTT assay.
Encouraged by the good performance of PS3 NPs in cel-
lular experiments, their potential for tumor inhibition was 
investigated in vivo. The murine models were established by 
subcutaneously injecting murine H22 cells into the right thigh. 
To explore the optimal time for light irradiation of PS3 NPs in 
Adv. Sci. 2019, 1802050
Figure 2. A) UV–vis absorption spectra and emission spectra of PS1 in THF, THF/water (v:v) = 2/3, and PS1 NPs in water (λex = 469 nm), inset: 
emission images of the PS1 and PS1 NPs under 365 nm UV illumination; B) UV–vis absorption spectra and emission spectra of PS2 in THF, THF/water 
(v:v) = 1/4, and PS2 NPs in water (λex = 469 nm), inset: emission images of the PS2 and PS2 NPs under 365 nm UV illumination; C) UV–vis absorption 
spectra and emission spectra of PS3 in THF, THF/water (v:v) = 2/3, and PS3 NPs in water (λex = 469 nm), inset: emission images of the PS3 and PS3 NPs 
under 365 nm UV illumination; D) Comparison of the decay rates of different PSs under irradiation (450 nm, 20 mW cm−2), A0 = absorption of ICG without 
irradiation. A = real-time absorption of ICG with different irradiation time; E) Time-dependent 1O2 generation kinetics. A0 = absorption of ICG without 
irradiation. A = real-time absorption of ICG with different irradiation time; F) Stability of size distribution of changes of different PSs during 14 d, inset: 
the TEM images of (a) PS1 NPs, (b) PS2 NPs, and (c) PS3 NPs. (PS1 or PS2 or PS3 or PS1 NPs or PS2 NPs or PS3 NPs) = 10−5 m, (ICG) = 6.5 × 10−6 m.
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vivo, IR780 was loaded in PS3 NPs. As shown in Figure S37 
(Supporting Information), the fluorescence intensity of NPs in 
the tumor gradually increased within 12 h and then decreased, 
which indicated that 12 h after injection is the optimal time for 
light irradiation. The tumor-bearing mice were then randomly 
divided into four groups and were intravenously injected with 
saline (groups 1), with saline and light (450 nm, 200 mW cm−2, 
20 min) (group 2), with PS3 NPs (100 µg mL−1, 100 µL) 
(group 3), and with PS3 NPs and light (group 4). The tumor 
volume and body weight of the mice were measured every 2 d 
for two weeks. As shown in Figure 4A–C, in the groups 1, 2, 
and 3, the relative tumor volumes showed a 8–9 times increase 
after 14 d, suggesting that only irradiation, or only PS3 NPs, 
has no influence on tumor growth. In contrast, the significantly 
Adv. Sci. 2019, 1802050
Figure 3. Cell viability of different PSs against HeLa cells A,C) under dark and B,D) under light (450 nm, 20 mW cm−2, 30 min); E) CLSM images 
of HeLa cells incubated with PS3 and PS3 NPs (20 µg mL−1) for 6 h, the scale bars are 20 µm; F) Generation of intracellular ROS mediated by PS3 
and PS3 NPs upon irradiation (450 nm, 20 mW cm−2, 20 min) as indicated by the fluorescence of DCF.
Figure 4. A) Representative images of mice. The hair on the thigh was removed immediately before irradiation. The images were taken on day 14 
after irradiation and the different hair length on the different mice is due to an inconsistent rate of hair growth. B) Harvested tumors from various 
groups treated (a) with saline, (b) with saline and light, (c) with PS3 NPs, (d) with PS3 NPs and light (100 mg mL−1, 100 µL), light irradiation (450 nm, 
200 mW cm−2, 20 min). C) Tumor volume measurement for different groups of mice (****, P < 0.0001, n = 5 per group, PDT vs other groups). D) Body 
weights of mice for different groups of mice.
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reduced tumor volume in the group 4 mice indicates the good 
antitumor performance of PS3 NPs under light irradiation, 
which is significantly different from the control groups. Fur-
thermore, the systemic toxicity of various treatments was 
evaluated via the mice’s body weight changes and the histo-
logical slices. In comparison with group 1, negligible body 
weight losses were observed in groups 2, 3, and 4 (Figure 4D). 
The mice were sacrificed at day 14, and major organs and 
the tumors were collected for hematoxylin and eosin (H&E) 
staining (Figure S36, Supporting Information). The PS3 NPs 
lead to destructive cell necrosis in the tumor under irradiation, 
indicating a severe cell injury. No pathological changes were 
found in the liver, heart, spleen, kidney, and lung in the four 
groups, indicating that PS3 NPs are not significantly toxic in 
vivo. These results reveal that PS3 NPs are suitable for in vivo 
PDT applications.
3. Conclusions
In summary, we have established for the first time that the 
efficiency of PDT can be enhanced by increasing the number 
of metal centers in PSs. Three red-emitting AIE Ir(III) com-
plexes with a different number of metal centers (mono-, di-, 
and trinuclear) and their corresponding NPs, were ration-
ally designed and synthesized. The molar absorption coef-
ficient increases with the number of metal centers, resulting 
in significantly improved 1O2 generation ability of the PSs. 
The nanoparticle formulation also further enhances the 
absorbance and 1O2 generation. In particular, the trinuclear 
PS3 NPs are excellent for PDT due to the following properties: 
λmaxem at ≈690 nm, high phosphorescence quantum yields 
(35%), long excited state lifetime (4.61 µs), high molar absorp-
tion coefficient (ɛ = 72 935 m−1 cm−1), excellent 1O2 generation 
ability, and negligible dark toxicity. Moreover, the PS3 NPs 
upon irradiation can efficiently inhibit tumor growth in mice 
after tail vein injection. This study provides new insights into 
the design of highly efficient PSs for PDT in clinical therapeu-
tics. Future work will include the development of multinuclear 
Ir(III) complexes with long excitation wavelength for in vivo 
imaging and PDT.
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